EOG RESOURCES INC — Director's Dealing 2023

Mar 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EOG RESOURCES INC (EOG)
CIK: 0000821189
Period of Report: 2023-03-10

Reporting Person: Yacob Ezra Y (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-10	Common Stock	M	15870	$96.29	Acquired	126039.357	Direct
2023-03-10	Common Stock	D	13410	$113.96	Disposed	112629.357	Direct
2023-03-10	Common Stock	F	968	$113.96	Disposed	111661.357	Direct
2023-03-10	Common Stock	M	9029	$75.09	Acquired	120690.357	Direct
2023-03-10	Common Stock	D	5950	$113.96	Disposed	114740.357	Direct
2023-03-10	Common Stock	F	1212	$113.96	Disposed	113528.357	Direct
2023-03-10	Common Stock	M	6013	$37.44	Acquired	119541.357	Direct
2023-03-10	Common Stock	D	1976	$113.96	Disposed	117565.357	Direct
2023-03-10	Common Stock	F	1589	$113.96	Disposed	115976.357	Direct
2023-03-10	Common Stock	M	3190	$49.86	Acquired	119166.357	Direct
2023-03-10	Common Stock	D	1396	$113.96	Disposed	117770.357	Direct
2023-03-10	Common Stock	F	706	$113.96	Disposed	117064.357	Direct
2023-03-10	Common Stock	M	12725	$81.81	Acquired	129789.357	Direct
2023-03-10	Common Stock	D	9136	$113.96	Disposed	120653.357	Direct
2023-03-10	Common Stock	F	1412	$113.96	Disposed	119241.357	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-10	Stock Appreciation Rights	$96.29	M	15870	Disposed	2024-09-25	Common Stock (15870)	Direct
2023-03-10	Stock Appreciation Rights	$75.09	M	9029	Disposed	2026-09-26	Common Stock (9029)	Direct
2023-03-10	Stock Appreciation Rights	$37.44	M	6013	Disposed	2027-09-28	Common Stock (6013)	Direct
2023-03-10	Stock Appreciation Rights	$49.86	M	3190	Disposed	2028-01-04	Common Stock (3190)	Direct
2023-03-10	Stock Appreciation Rights	$81.81	M	12725	Disposed	2028-09-27	Common Stock (12725)	Direct

Footnotes

F1: The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 25, 2017 date of grant. The SARs granted became fully exercisable on September 25, 2020. This exercise did not involve any open-market sale of the Issuer's Common Stock.

F2: The SARs granted became exercisable in increments of 33%, 33% and 34% on each of the first three anniversaries, respectively, of the September 26, 2019 date of grant. The SARs granted became fully exercisable on September 26, 2022. This exercise did not involve any open-market sale of the Issuer's Common Stock.

F3: The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the September 28, 2020 date of grant. The SARs granted will become fully exercisable on September 28, 2023. This exercise did not involve any open-market sale of the Issuer's Common Stock.

F4: The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the January 4, 2021 date of grant. The SARs granted will become fully exercisable on January 4, 2024. This exercise did not involve any open-market sale of the Issuer's Common Stock.

F5: The SARs granted become exercisable in increments of 33.3%, 33.3% and 33.4% on each of the first three anniversaries, respectively, of the September 27, 2021 date of grant. The SARs granted will become fully exercisable on September 27, 2024. This exercise did not involve any open-market sale of the Issuer's Common Stock.